- Home
- ARHS vs TBPH Comparison
ARHS vs TBPH Comparison
Compare ARHS & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ARHS | TBPH |
|---|---|---|
| Founded | 1986 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 956.8M | 824.9M |
| IPO Year | 2021 | 2013 |
Fundamental Metrics
Financial Performance| Metric | ARHS | TBPH |
|---|---|---|
| Price | $7.05 | $16.99 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 6 |
| Target Price | $10.78 | ★ $18.40 |
| AVG Volume (30 Days) | ★ 1.1M | 408.8K |
| Earning Date | 05-07-2026 | 05-04-2026 |
| Dividend Yield | ★ 4.78% | N/A |
| EPS Growth | N/A | ★ 279.13 |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $1,379,222,000.00 | $15,386,000.00 |
| Revenue This Year | $7.23 | $8.46 |
| Revenue Next Year | $7.10 | N/A |
| P/E Ratio | $347.50 | ★ N/A |
| Revenue Growth | ★ 8.51 | N/A |
| 52 Week Low | $5.57 | $10.82 |
| 52 Week High | $12.97 | $21.03 |
Technical Indicators
Market Signals| Indicator | ARHS | TBPH |
|---|---|---|
| Relative Strength Index (RSI) | 53.67 | 61.15 |
| Support Level | $6.19 | $16.12 |
| Resistance Level | $7.62 | $17.21 |
| Average True Range (ATR) | 0.41 | 0.36 |
| MACD | 0.05 | 0.07 |
| Stochastic Oscillator | 56.94 | 92.41 |
Price Performance
Historical ComparisonAbout ARHS Arhaus Inc.
Arhaus Inc is a growing lifestyle brand and omnichannel retailer of premium home furniture. The company offers merchandise in several categories, including furniture, outdoor, lighting, textiles, and decor through its Retail and e-commerce sales channels.
About TBPH Theravance Biopharma Inc.
Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.